Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO WCGIC 2021

30 Jun–03 July 2021 | Virtual Meeting

ESMO WCGIC 2021

30 Jun–03 July 2021 | Virtual Meeting
Impact of timing of perioperative chemotherapy on OS in patients with CRC liver metastases 2:35
Impact of timing of perioperative chemotherapy on OS in patients with CRC liver metastases
Firas Baidoun • 7 Jul 2021
Tislelizumab in patients with unresectable HCC demonstrates durable responses 2:58
Tislelizumab in patients with unresectable HCC demonstrates durable responses
Ghassan Abou-Alfa • 25 Jun 2021
1L NALIRIFOX in advanced or metastatic PDAC 0:40
1L NALIRIFOX in advanced or metastatic PDAC
Zev Wainberg • 1 Jul 2021
Impact of gender and HPV status on anal squamous cell carcinoma survival 1:37
Impact of gender and HPV status on anal squamous cell carcinoma survival
Firas Baidoun • 7 Jul 2021
Monitoring MRD by ctDNA in resectable CRC 2:49
Monitoring MRD by ctDNA in resectable CRC
Hiromichi Shirasu • 1 Jul 2021
Treating CRC with regorafenib in Latin America 1:25
Treating CRC with regorafenib in Latin America
Juan Manuel O'Connor • 28 Jun 2021
CRC highlights from ESMO WCGIC 2021 1:12
CRC highlights from ESMO WCGIC 2021
Juan Manuel O'Connor • 28 Jun 2021
Tiragolumab and atezolizumab in metastatic esophageal cancer 0:39
Tiragolumab and atezolizumab in metastatic esophageal cancer
Zev Wainberg • 30 Jun 2021
KEYNOTE-811: trastuzumab + chemotherapy with or without pembrolizumab for HER2+ G/GEJ cancer 1:40
KEYNOTE-811: trastuzumab + chemotherapy with or without pembrolizumab for HER2+ G/GEJ cancer
Yelena Y. Janjigian • 28 Jun 2021
MATTERHORN: neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable G/GEJ 2:00
MATTERHORN: neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable G/GEJ
Yelena Y. Janjigian • 28 Jun 2021
Treatment of CRC in adjuvant setting 1:09
Treatment of CRC in adjuvant setting
Deborah Mukherji • 25 Jun 2021
BEACON CRC: first-line bevacizumab in colorectal cancer treatment 8:16
BEACON CRC: first-line bevacizumab in colorectal cancer treatment
Dan Aderka • 25 Jun 2021
Averectal: neoadjuvant short-course RT followed by chemo + avelumab in rectal adenocarcinoma 3:51
Averectal: neoadjuvant short-course RT followed by chemo + avelumab in rectal adenocarcinoma
Ali Shamseddine • 22 Jun 2021
Updates to look out for at ESMO WCGIC 2021 1:05
Updates to look out for at ESMO WCGIC 2021
Lei Deng • 29 Jun 2021
Early colon and rectal cancer at ESMO WCGIC 2021 2:33
Early colon and rectal cancer at ESMO WCGIC 2021
Deborah Mukherji • 25 Jun 2021
VALENTINO: VAF as prognostic marker in mCRC 2:19
VALENTINO: VAF as prognostic marker in mCRC
Paolo Manca • 24 Jun 2021
The content of VJOncology is intended for healthcare professionals